Chapter 3 Death and Survival on Dialysis Wong Hin Seng Ong Loke Meng Source: 20 th MDTR Report 2012, NRR.

Slides:



Advertisements
Similar presentations
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
Advertisements

CHAPTER 7: Nutritional Status on Dialysis Abdul Halim B Abd Gafor Winnie Chee Siew Swee Tilakavati Karupaiah Koh Keng Hee Ahmad Fauzi B Abd Rahman Source:
This Power Point presentation belongs to the Danish Renal Registry, which owns the copyright. It can be freely used for non-commercial study and educational.
UK Renal Registry 15th Annual Report Figure One year death rate per 1,000 patient years by UK country and age group for prevalent dialysis.
Chapter 12: USRDS Special Study Center on Transition of Care in CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Chapter 5: Acute Kidney Injury 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
UK Renal Registry 16th Annual Report Figure Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2012.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
UK Renal Registry 17th Annual Report Figure 8.1. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
UK Renal Registry 17th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2013.
CHAPTER 12 Peritoneal Dialysis Sunita Bavanandan Lily Mushahar Anita Bhajan Manocha Source: 20 th MDTR Report 2012, NRR.
Chapter 4: Quality of life and rehabilitation outcomes of patients on Dialysis Liu Wen Jiun Chew Thian Fook Christopher Lim Thiam Seong Tan Wee Ming Yia.
UK Renal Registry 14th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2010.
UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate
UK Renal Registry 10th Annual Report 2007 Fig 3.1 Incident rates in the countries of the UK:
CHAPTER 5: PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail Source: 21 st MDTR.
CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 21 st MDTR Report 2013, NRR.
CHAPTER 13 RENAL TRANSPLANTATION Editor: Dr. Goh Bak Leong Expert Panel: Dato’ Dr. Zaki Morad b Mohd Zaher (Chair) Dr. Goh Bak Leong (Co-Chair) Dr. Fan.
CHAPTER 1: ALL RENAL REPLACEMENT THERAPY IN MALAYSIA Lim Yam Ngo Ong Loke Meng Goh Bak Leong Lee Day Guat Source: 20 th MDTR Report 2012, NRR.
UK Renal Registry 17th Annual Report Figure 1.1. RRT incidence rates in the countries of the UK 1990–2013.
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
CHAPTER 6: MANAGEMENT OF ANAEMIA IN PATIENTS ON DIALYSIS Philip N. Jeremiah Bee Boon Cheak Ghazali B Ahmad Lim Soo Kun Zawawi B Nordin Source: 21 st MDTR.
UK Renal Registry 15th Annual Report Figure 6.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2011.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.
UK Renal Registry 16th Annual Report Figure Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
CHAPTER 9: Chronic Kidney Disease – Mineral and Bone DisorderKok Lai Sun Ching Chen Hua Fan Kin Sing Rozina Ghazalli Liew Yew Fong Source: 21 st MDTR Report.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 10: Dialysis Providers.
CHAPTER 8: Blood Pressure Control and Dyslipidaemia in Patients on Dialysis S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 21 st.
CHAPTER 11 Haemodialysis Practices Tan Chwee Choon Shahnaz Shah Firdaus Khan Rafidah Abdullah Norleen Bt Zulkarnain Sim Source: 20 th MDTR Report 2012,
Chapter 5: Acute Kidney Injury 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
CHAPTER 13 Renal Transplantation Goh Bak Leong Fan Kin Sing Rohan Malek Bin Dato’ Dr. Johan Rosnawati Yahya S. Prasad Menon Tan Si Yen Wong Hin Seng Source:
Chapter 1 ALL RENAL REPLACEMENT THERAPY IN MALAYSIA
UK Renal Registry 10th Annual Report 2007 Fig 9.1 Annual change in percentage of dialysis patients with serum phosphate < 1.8mmol/L and ≥1.1 -≤1.8mmol/L.
What happens to patients returning to dialysis after transplant failure? Data from the UK Renal Registry Dr Lynsey Webb 1, Dr Anna Casula 1, Dr Charlie.
MANAGEMENT OF ANAEMIA IN PATIENTS ON DIALYSIS Philip N. Jeremiah Bee Boon Cheak Ghazali B Ahmad Lim Soo Kun Zawawi B Nordin Source: 20 th MDTR Report 2012,
CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 20 th MDTR Report 2012, NRR.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.
Date of download: 6/22/2016 From: Biomarkers of Inflammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease:
CHAPTER 8: BLOOD PRESSURE CONTROL AND DYSLIPIDAEMIA S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 20 th MDTR Report 2012, NRR.
Table S1. Logistic regression analysis for the variables associated with the degree of change in cTnT between 2 time points (n=89) UnivariateMultivariate.
Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
2016 Annual Data Report, Vol 2, ESRD, Ch 6
UK Renal Registry 18th Annual Report
First-year death rates by modality figure 8
UK Renal Registry 10th Annual Report 2007
Mortality rates in incident ESRD patients figure 9
Fig 7.1 Median URR achieved in each renal unit
UK Renal Registry 16th Annual Report
UK Renal Registry 18th Annual Report
CHAPTER 5 Paediatric Renal Replacement Therapy
Table 4.1: Cumulative distribution of QoL-Index score in relation to dialysis modality, all dialysis patients
CHAPTER 7 Nutritional Status on Dialysis
CHAPTER 11: Haemodialysis Practices
CHAPTER 3 Death and Survival on Dialysis
CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition
CHAPTER 9 Chronic Kidney Disease – Mineral and Bone Disorder
Christopher Lim Thiam Seong
CHAPTER 10 Hepatitis on Dialysis
UK Renal Registry 14th Annual Report
Volume 76, Issue 10, Pages (November 2009)
2013 Annual Report - 36th Edition
Chapter 7 Nutritional status on dialysis
UK Renal Registry 14th Annual Report
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
CHAPTER 10 Hepatitis on Dialysis
Figure Prevalence of coronary artery disease by year or
Stock and Flow of Haemodialysis Patients Australia
Presentation transcript:

Chapter 3 Death and Survival on Dialysis Wong Hin Seng Ong Loke Meng Source: 20 th MDTR Report 2012, NRR

Table 3.1.1: Deaths on dialysis Source: 20 th MDTR Report 2012, NRR

Figure 3.1.1: Death rates on dialysis Source: 20 th MDTR Report 2012, NRR

Table (a) : Causes of death on HD dialysis Source: 20 th MDTR Report 2012, NRR

Table (b) : Causes of death on PD dialysis Source: 20 th MDTR Report 2012, NRR

Table 3.2.1(a): HD Patient survival (censored for change of modality) Dialysis Modality Interval (month) HD n% survivalSE Source: 20 th MDTR Report 2012, NRR

Table 3.2.1(b): PD Patient survival (censored for change of modality) Dialysis Modality Interval (month) PD n% survivalSE Source: 20 th MDTR Report 2012, NRR

Table 3.2.1(c): HD Patient survival (not censored for change of modality) Dialysis Modality Interval (month) HD n% survivalSE Source: 20 th MDTR Report 2012, NRR

Table 3.2.1(d): PD Patient survival (not censored for change of modality) Dialysis Modality Interval (month) PD n% survivalSE Source: 20 th MDTR Report 2012, NRR

Table 3.2.2(a): Unadjusted HD patient survival by year of entry, Source: 20 th MDTR Report 2012, NRR

Figure 3.2.2(a): Unadjusted HD patient survival by year of entry, Source: 20 th MDTR Report 2012, NRR

Table 3.2.2(b): Unadjusted PD patient survival by year of entry, Source: 20 th MDTR Report 2012, NRR

Figure 3.2.2(b): Unadjusted PD patient survival by year of entry, Source: 20 th MDTR Report 2012, NRR

Table 3.2.3(a): Unadjusted HD patient survival by age, Source: 20 th MDTR Report 2012, NRR

Figure 3.2.3(a): Unadjusted HD patient survival by age, Source: 20 th MDTR Report 2012, NRR

Table 3.2.3(b): Unadjusted PD patient survival by age, Source: 20 th MDTR Report 2012, NRR

Figure 3.2.3(b): Unadjusted PD patient survival by age, Source: 20 th MDTR Report 2012, NRR

Table 3.2.4(a): Unadjusted HD patient survival by diabetes mellitus status, Diabetes status Interval (month) Non-diabeticDiabetic n% survivalSEn% survivalSE Source: 20 th MDTR Report 2012, NRR

Figure 3.2.4(a): Unadjusted HD patient survival by diabetes mellitus status, Source: 20 th MDTR Report 2012, NRR

Table 3.2.4(b): Unadjusted PD patient survival by diabetes mellitus status, Diabetes status Interval (month) Non-diabeticDiabetic n% survivalSEn% survivalSE Source: 20 th MDTR Report 2012, NRR

Figure 3.2.4(b): Unadjusted PD patient survival by diabetes mellitus status, Source: 20 th MDTR Report 2012, NRR

Figure 3.3.1(a): Variation in patient survival at 1-year among HD centres adjusted for age and diabetes mellitus status, Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the median % survival among HD centres

Figure 3.3.1(b): Funnel plot for adjusted age at 1-year among HD centres adjusted for age and diabetes mellitus status, cohor Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the mean % survival among HD centres

Figure 3.3.1(c): Variation in patient survival at 5-years among HD centres adjusted for age and diabetes mellitus status, Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the median % survival among HD centres

Figure 3.3.1(d): Funnel plot for patient survival at 5-years among HD centres adjusted age and diabetes mellitus, cohort Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the mean % survival among HD centres

Figure 3.3.2(a): Variation in patient survival at 1-year among PD centres adjusted for age and diabetes mellitus, Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the median% survival among PD centres

Figure 3.3.2(b): Funnel plot of 1-year patient survival from the 90th day of dialysis adjusted for age and diabetes mellitus among PD centres, cohort Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the mean % survival among PD centres

Figure 3.3.2(c): Variation in patient survival at 5-years among PD centres adjusted for age and diabetes mellitus, Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the mean % survival among PD centres

Figure 3.3.2(d): Funnel plot of 5-years patient survival from 90 day of dialysis adjusted for age and diabetes mellitus among PD centres, cohort Source: 20 th MDTR Report 2012, NRR *Horizontal line represents the median% survival among PD centres

Table 3.4.1: Adjusted hazard ratio for mortality of dialysis patients (not censored for change of modality ( ) )

Figure 3.4.1(a): Adjusted hazard ratio for mortality of dialysis patients uncensored for change of modality by diastolic blood pressure ( cohort) Source: 20 th MDTR Report 2012, NRR Hazard ratio <7070-<8080-<90(ref*)90-<100>=100 Diastolic Blood Pressure (mmHg)

Figure 3.4.1(b): Adjusted hazard ratio for mortality of dialysis patients uncensored for change of modality by serum phosphate ( cohort) Source: 20 th MDTR Report 2012, NRR Hazard ratio < (ref*) >=2.2 Serum Phosphate (mmol/L)

Figure 3.4.1(c): Adjusted hazard ratio for mortality of dialysis patients uncensored for change of modality by hemoglobin ( cohort) Source: 20 th MDTR Report 2012, NRR Hazard ratio < <4.5 (ref*)4.5-<5.5>=5.5 Calcium Phosphate Product (mmol2/L2)

Table 3.4.2: Adjusted hazard ratio for mortality of HD patients uncensored for change of modality ( cohort)

Figure 3.4.2: Adjusted hazard ratio for mortality of HD patients uncensored for change of modality by Prescribed Kt/V ( cohort) Source: 20 th MDTR Report 2012, NRR Hazard ratio <11-< <1.4(ref*)1.4-<1.6>=1.6 Prescribed KT/V-HD

Table 3.4.3: Adjusted hazard ratio for mortality of PD patients uncensored for change of modality ( cohort)

Figure 3.4.4(a): Variations in RAMR by HD centre, 2011 Source: 20 th MDTR Report 2012, NRR

Figure 3.4.4(b): Funnel plot of RAMR by HD centre, 2011 Source: 20 th MDTR Report 2012, NRR

Figure 3.4.5(a): Variations in RAMR by PD centres, 2011 Source: 20 th MDTR Report 2012, NRR

Figure 3.4.5(b): Funnel plot for RAMR by PD centres, 2011 Source: 20 th MDTR Report 2012, NRR